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ABSTRACT
Breast cancer is a heterogeneous disease with regard to morphological spectrum, clinical
presentation and response to therapy. Based on immunohistochemistry detection of estrogen
receptor, progesterone receptor, Her-2 status, proliferation rate and clusters of basal gene
expression, breast cancers can be classified into luminal A, luminal B, basal-like/triple negative,
and Her-2 positive. It was suggested that there was a close relationship between molecular
subtypes and clinicopathological features of breast cancer, as they are very important to predict
prognosis and therapeutic implications.
ABSTRAK
Kanker payudara merupakan penyakit yang heterogen dalam spectrum morfologi, manifestasi
klinis dan respon terapi. Deteksi imunohistokimiawi dengan marker estrogen receptor, progesterone
receptor, status Her-2, proliferasi dan ekspresi berbagai kluster gen sel basal, mengelompokkan
kanker payudara menjadi berbagai subtype: luminal A, luminal B, basal-like/ triple negative, dan
Her-2 positif. Subtipe molecular kanker payudara nampaknya juga berhubungan erat dengan
klinik optologis dan sangat penting untuk memprediksi prognosis dan menentukan terapi
penderita.
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INTRODUCTION
Breast cancer is a heterogeneous disease
that has different prognoses and responses to
therapy despite the similarities in histological
type, grade and stage. The heterogeneity of
breast cancer cannot be explained only by
clinical parameters such as tumor size, lymph
node involvement, histological grade, age, or
by biomarkers like estrogen receptor (ER),
progesterone receptor (PR) and epidermal
growth factor receptor 2 (Her-2) which is
routinely used in the diagnosis and treatment of
patients.1,2 It is believed that different clinical
behaviors of breast cancer are due to molecular
differences. A better understanding of breast
tumor heterogeneity and the nature of tumor-
propagating cells requires delineation of the
mammary epithelial subtypes that reside within
normal human breast tissue. Therefore, tracing
of specific mammary epithelial cells is
important to definitely identify cells of origin
for the different tumor types.3Breast cancer can
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be consistently categorized into subtypes with
derivation from the normal basal and luminal
mammary epithelial cells.4,5
Recent development of high molecular
method offers new opportunities to capture the
wide range of genomic and biologic variability
in breast cancers. The molecular classification
of breast cancers using microarray technique is
limited to fresh/frozen samples. Therefore,
several studies have tried to define immuno-
histochemical or quantitative real time reverse
transcript as polymerase chain reaction (RT-
PCR) using formalin-fixed paraffin-embedded
samples, for identification of themolecular
subtypes.6
A pioneer study done by Perou et al.7 using
gene-expression signature, classified breast
cancers into two main subgroups, namely ER
positive and ER negative cancers. The ER
positive cancers comprise of the luminal tumors
which can be subdivided into at least two
distinct subgroups, namely luminal A and
luminal B. The ER negative cancers consist of
at least three subgroups of cancers, i.e. Her-2
positive, basal-like/triple negative and normal-
like cancers. The types of breast cancer that do
not fulfill those criteria belong to unclassified
cancer.8,9
Several studies proved that molecular
subtyping of breast cancer has a close
relationship with clinicopathological features
and is very important to predict clinical outcome
and response to therapy. This article is focused
on discussing the molecular subtypes and
clinicopathological features of breast cancer.
DISCUSSION
Breast cancer, a leading cause of cancer
death in women, is recognized to be a mole-
cularly heterogeneous tumor. Histologically,
similar tumors may have different prognoses and
treatment responses that clearly are due to
molecular differences. Molecular profiling,
based upon variations in gene expression, has
been used to characterize breast cancers beyond
the conventional use of grade, histology and
immunohistochemical analysis of hormone
receptors and Her-2 over-expression.10 Normal
breast ducts are lined by two distinct
differentiated cell types, luminal cells lining the
apical surface of the duct and myoepithelial cells
that reside within the basal layer. Therefore,
breast cancer can be categorized into subtypes
that are consistent with derivation from the
normal basal and luminal mammary epithelial
cells.4,5
Gene expression studies have identified
several distinct breast cancer subtypes. These
include two main subtypes of ER positive
cancers (luminal A and luminal B) and at least
three ER negative cancers (basal-like/ triple
negative, Her-2 positive and normal-like).
These subtypes are different markedly in
prognosis and therapeutic implications. Genes
that differentiate these subtypes are called the
intrinsic genes and made up of several clusters
of genes relating to ER, PR expression, Her-2
expression, proliferation and cluster of basal
genes.6
The luminal A cancers include 56% ductal
and 23% lobular carcinoma, while most (75-
89%) of luminal B, basal-like/triple negative
and Her-2 positive cancers are ductal
carcinoma.11 In general, the luminal A cancers
have the best prognosis, while the luminal B
cancers suffer a significantly worse outcome.
Both the basal-like/triple negative and Her-2
positive cancer have the worst survival rate,
until the era of Her-2 targeting has altered the
outcome for the Her-2 subtypes and Her-2
luminal cancers. The luminal A cancers
generally require ER inhibitors such as
tamoxifen and aromatase inhibitors, which is
also a part of the treatment of the luminal B
cancers. Chemotherapy is indicated for most
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patients with the luminal B, Her-2 positive and
basal-like/triple negative, with the addition of
trastuzumab I to Her-2 positive cancers.10The
normal-like breast cancer is rather poorly
understood. One of the main characteristics of
these cancers is that they consistently cluster
together with samples of normal breast and
fibroadenomas.6
The prevalence of molecular breast cancer
subtypes varies among races. A study in Egypt
found that luminal A subtype was the most
prevalent (41.2%), followed by triple negative
subtype (28.5%), then Her-2 subtype (19.4%)
and luminal B subtype (13.9%).12 In Chinese
women, the prevalence of luminal A, luminal
B, Her-2 and triple negative subtypes were
48.6%, 16.7%, 13.7% and 12.9%, respecti-
vely.13Among youngAfrican-American women,
basal-like cancers occurred with higher
prevalence compared with luminal cancers.8
Among breast cancer women in north-east of
Morocco, luminalAsubtype was more prevalent
(53.6%) and associated with favorable clinic-
pathological characteristics, followed by
luminal B (16.4%), Her2-overexpressing
(12.6%), basal-like (12.6%) and unclassified
subtype (4.9%).14
The luminal cancers
The luminal cancers, called luminal A and
luminal B, are expressed genes that are also
expressed by normal breast luminal epithelial
cells cytokeratine 8 and 18. Most of breast
cancers (60%) are luminal cancers. The luminal
cancer cells look the most like the cells of breast
cancers that start in the inner (luminal) cells
lining the mammary ducts. The luminal cancers
are characterized by expression of ER, PR and
other genes associated with ER activation.10,15
The luminal A cancers have a greater
frequency of small cancer (d” 2cm) and tend to
have the best prognosis in comparison to the
other breast cancer subtypes.11 These cancers
have a low or moderate tumor grade and only
12-15% of them have p53 mutation, a factor
l inked with a poorer prognosis.8 The typical
immunohistochemical profiles of luminal type
A breast cancers are ER positive and or PR
positive, Her-2 negative and low proliferation
rate. The recurrence rate of this cancer is
27.8%—significantly lower than that for other
subtype. Survival from the time of relapse of
these cancers is also longer (median 2.2
years).2,16
The luminal B cancers could represent a
more aggressive phenotype and are often
diagnosed at a younger age than the luminal A
ones. The main biological difference between
luminal A and B is an increased expression of
proliferation genes, such as Ki-67 and cyclin
B1 in the luminal B subtype which also
expresses EGFR and Her-2. Some researchers
classify luminal B tumors in the ER-positive
subgroup with poor prognosis.17,18 Luminal B
tumor shave a worse prognosis than luminal A
tumors. The bone is still the most common site
of recurrence (30%) of this tumor. The survival
rate from time of relapse is low (1.6 years).17
The treatment of luminal A subgroup of
breast cancer is mainly based on third-
generation hormonal aromatase inhibitors in
postmenopausal patients, selective estrogen
receptor modulators (SERMs) like tamoxifen
and pure selective regulators of ER like
fulvestrant. These cancers were less responsive
to chemotheraphy.2,16
The luminal B cancers, despite being treated
with tamoxifen and aromatase inhibitor, also
respond better to neoadjuvant chemotherapy
achieving pathological complete response
(pCR) in 17% of the luminal B tumors (7% in
luminal A), however, this is clearly lower than
for the Her-2 and basal-like tumors with values
of 36% and 43%, repectively.19 For luminal B
cancers, the panel considers that both
anthracyclines and taxanes should be included
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in the chemotherapy regimens.19 For those
reasons, treatment of this subtype of breast
cancer is currently challenging.
The basal-like/triple negative cancers
The basal-like subtypes are named based
on the many gene characteristics of normal breast
basal epithelial cells that they express. Most
triple negative tumors are basal-like, and most
basal-like tumors are triple negative. However,
not all triple negative tumors are basal-like
tumors and not all basal-like tumors are triple
negative. About 15-20% of breast cancers are
triple negative or basal-like.2 Basal-like cancers
can occur due to the alteration of BRCA-I gene
function, either by mutation or by epigenetic
mechanisms. BRCA-1 gene is critical in the
DNA repair and its inactivation leads to the
accumulation of errors and genetic instability
favoring the tumor growth.20 Clinically, basal-
like/triple negative cancers are characterized
by their appearance at an early age women, with
large tumor size at diagnosis, a high histological
grade and a high frequency of lymph node
metastasis.20Basal-like cancers tend to be breast
cancer with a high mitotic index, tumor necrosis,
and the pattern of metastatic relapse that are
predominantly to the lung, central nervous
system and lymph node. These cancers have a
higher relapse rate in the first 3 years, despite
presenting a high response to chemotherapy.1
The high rate of p53 mutation in these cancers
may explain their aggressiveness and poor
prognosis. Therefore, it is critical to find new
therapeutic targets and design appropriate
treatment strategies.1
Basal-like/triple negative cancers are
usually treated with some combinations of
surgery, radiation therapy and chemotherapy.
These tumors cannot be treated with hormone
therapies or trastuzumab (Herceptin®) because
they are hormone receptor-negative and Her-2
negative. The genes linked to basal-like tumors
are not well understood and thus, targeted
therapies do not yet exist. However, there are
potential targets for future therapies including
the EGF receptor, aB-crystalin and cyclin E.21
The Her-2 subtype cancers
About 10-15% of breast cancers are Her-2
subtype. They are characterized by low
expression of luminal clusters, high expression
of the Her-2 gene and other genes associated
with the Her-2 pathway and/or Her-2 amplifi-
cation located in the 17q 12 chromosomes.
These tumors also have a high proliferative rate.
75% have a high histological grade and more
than 40% have p53 mutation.19 From clinical
point of view, Her-2 type tumors have a fairly
poor prognosis and are prone to early recurrence
and metastases. Women with Her-2 type tumors
appear to be diagnosed at a younger age than
those with luminal tumors.2,22
A humanized monoclonal anti Her-2
antibody, trastuzumab, is offered for early and
advanced breast cancer patients whose tumors
have Her-2 3+immunohistochemial expression
or Her-2 gene amplification. Novel therapeutic
strategies have been proposed, for example
monoclonal antibodies that are allegedly more
effective in blocking Her-2 heterodimerization
(e.g. pertuzumab)23 and Her-2 tyrosine kinase
inhibitors (e.g. lapatinib) in clinical trials.24Both
Her-2 subtype and the basal-like subtype have
a high chemosensitivity with higher response
rate than that of luminal tumors, in the neo-
adjuvant study.19
CONCLUSION
Based on gene expression profiling or
immunohistochemical characteristics, breast
cancer can be classified into four major
subtypes: luminal A, luminal B, Her-2 positive
and basal-like/triple negative. Several studies
suggest that there is a close relationship between
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molecular subtypes and clinicopathological
features of breast cancer. Molecular subtyping
of breast cancer becomes useful in predicting
prognosis, planning treatment and developing
new therapies.
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